No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L clinical trials

Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

This study looks at how to best prevent infections in people with multiple myeloma receiving new treatments called BCMA-directed T-cell engagers. It compares two different amounts of immunoglobulin support to see which is better at reducing severe infections.